AstraZeneca ((AZN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca is conducting a study titled ‘A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD9793, a T Cell-engaging Antibody Targeting Glypican-3 (GPC3) in Adult Participants With Advanced or Metastatic Solid Tumours (RHEA-1)’. The study aims to assess the safety, tolerability, and anti-cancer activity of AZD9793 in patients with advanced or metastatic solid tumors that are GPC3 positive.
The intervention being tested is AZD9793, a T cell-engaging antibody targeting GPC3. It is administered in two forms: intravenous (IV) and subcutaneous (SC) monotherapy, designed to engage T cells to attack tumor cells.
The study is interventional with a non-randomized, sequential model. It consists of two modules, each with dose escalation and expansion phases, and is open-label, meaning no masking is involved. The primary purpose is treatment-focused.
The study began on January 8, 2025, with the latest update on August 27, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
This clinical update could positively influence AstraZeneca’s stock performance by showcasing innovation in cancer treatment, potentially enhancing investor confidence. It also positions AstraZeneca competitively in the oncology sector, which is witnessing rapid advancements.
The study is currently recruiting, with further details available on the ClinicalTrials portal.